ArticleCardiovascular drugs and therapy2018

Effect of Anagliptin and Sitagliptin in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: What Is the Real REASON Behind It?

Venu Gopal Jonnalagadda et al.PubMed ↗Publisher ↗

No numbers read from the abstract.